DCLK1 as a Promising Marker for Radioresistance in Colorectal Cancer

被引：3
|
作者：
Mohammadi, Chiman [1 ]
Najafi, Rezvan [1 ]
机构：
[1] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Hamadan, Iran
来源：
JOURNAL OF GASTROINTESTINAL CANCER | 2020年 / 51卷 / 02期
关键词：
D O I：
10.1007/s12029-019-00292-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：714 / 715
页数：2
相关论文
共 50 条
  • [21] DCLK1 and its oncogenic functions: A promising therapeutic target for cancers
    Ye, Liu
    Liu, Beibei
    Huang, Jingling
    Zhao, Xiaolin
    Wang, Yuan
    Xu, Yungen
    Wang, Shuping
    LIFE SCIENCES, 2024, 336
  • [22] The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer (vol 9, pg 346, 2014)
    Vedeld, Hege Marie
    Skotheim, Rolf I.
    Lothe, Ragnhild A.
    Lind, Guro E.
    EPIGENETICS, 2016, 11 (08) : 635 - 635
  • [23] Regulation of Angiogenic Factors by DCLK1 in Pancreatic Cancer
    Sureban, S. M.
    May, R.
    Weygant, N.
    Qu, D.
    Houchen, C. W.
    PANCREAS, 2013, 42 (08) : 1383 - 1384
  • [24] Pleiotropic effects of DCLK1 in cancer and cancer stem cells
    Chhetri, Dibyashree
    Vengadassalapathy, Srinivasan
    Venkadassalapathy, Santhosh
    Balachandran, Varadharaju
    Umapathy, Vidhya Rekha
    Veeraraghavan, Vishnu Priya
    Jayaraman, Selvaraj
    Patil, Shankargouda
    Iyaswamy, Ashok
    Palaniyandi, Kanagaraj
    Gnanasampanthapandian, Dhanavathy
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [25] Research Progress of DCLK1 Inhibitors as Cancer Therapeutics
    Cheng, Linna
    Huang, Shenzhen
    Chen, Lijuan
    Dong, Xiaoyan
    Zhang, Lei
    Wu, Chengye
    Ye, Kaihong
    Shao, Fengmin
    Zhu, Zunmin
    Thorne, Rick F.
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (13) : 2261 - 2273
  • [26] Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells
    Lianna Li
    Hao Mei
    Abednego Nii Adom Commey
    Cancer Gene Therapy, 2020, 27 : 691 - 701
  • [27] Regulation of Pluripotency Markers by DCLK1 in Pancreatic Cancer
    Sureban, S. M.
    May, R.
    Qu, D.
    Ali, N.
    Houchen, C. W.
    PANCREAS, 2012, 41 (08) : 1407 - 1407
  • [28] DCLK1 Promotes Cisplatin Resistance in Ovarian Cancer
    Dogra, Samrita
    Moxley, Katherine
    Hannafon, Bethany N.
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (10 S): : S1 - S1
  • [29] Can DCLK1 be a biomarker for head and neck cancer?
    Yasasever, C. Tilgen
    Dogru, E. Bilgin
    Serilmez, M.
    Ahmet, K.
    Karaman, S.
    FEBS OPEN BIO, 2018, 8 : 318 - 318
  • [30] Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism
    Sureban, Sripathi M.
    Madhoun, Mohammad F.
    May, Randal
    Qu, Dongfeng
    Ali, Naushad
    Fazili, Javid
    Weygant, Nathaniel
    Chandrakesan, Parthasarathy
    Ding, Kai
    Lightfoot, Stanley A.
    Houchen, Courtney W.
    ONCOTARGET, 2015, 6 (35) : 37200 - 37215
12345